Stanford, California 94305

  • Epidermolysis Bullosa Dystrophica


Recessive dystrophic epidermolysis bullosa (RDEB) is a disease caused by genetic mutations in the gene for type VII collagen. Patients with RDEB develop large, severely painful blisters and open wounds from minor trauma to their skin. We are screening subjects with RDEB to evaluate characteristics of the subjects and their cells in order to develop new strategies of therapy and determine whether subjects could be candidates for treatment studies.

Study summary:

We will obtain a detailed medical history and will perform a skin examination and brief physical exam. Photographs may be taken. We will ask questions about the size and duration wounds. LAB TESTS We will draw blood to determine overall health status to include Hepatitis B, Hepatitis C, and Human Immunodeficiency Virus (HIV) testing. Genetic testing may also be performed. BIOPSIES Biopsies may be collected to check for Collagen 7 and for antibodies to Collagen 7. Based on the results obtained, it may be possible to identify patients who would qualify to participate in current or future clinical trials.


Inclusion Criteria: - Clinical diagnosis of RDEB by local dermatologist - 7 years of age or older Exclusion Criteria: -Medical instability limiting ability to travel to Stanford University Medical Center



Primary Contact:

Principal Investigator
Jean Tang, MD, PhD
Stanford University

Irene Bailey-Healy
Phone: (650) 721-7149

Backup Contact:

Nicki Harris

Location Contact:

Stanford, California 94305
United States

Irene Bailey-Healy
Phone: 650-721-7149

Site Status: Recruiting

Data Source:

Date Processed: September 27, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.